Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important role. We propose to assess BAT activity, using infrared thermography camera images, before individuals start weekly administration of semaglutide, at week 2-4, and week 18-20. We hypothesize that this GLP-1 agonist, semaglutide, will cause an increase in BAT activity and a corresponding increase in basal metabolic rate.
Conditions:
🦠 Obesity
🗓️ Study Start (Actual) 1 February 2023
🗓️ Primary Completion (Estimated) 1 January 2025
✅ Study Completion (Estimated) 1 June 2025
👥 Enrollment (Estimated) 20
🔬 Study Type OBSERVATIONAL
📊 Phase N/A
Locations:
📍 Los Angeles, California, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study)
    • * \>18 years of age and willing to participate
    • * Male or post-menopausal females

    Exclusion Criteria:

    • * History of prior neck surgery and /or neck irradiation
    • * Use of beta blocker agents
    • * Use of any other glucose lowering medication
    • * History of neuropathic disorders (e.g. diabetic neuropathy)
    • * Diabetic patients
    • * Individuals without normal thyroid function
    • * Individuals with cancer
    • * Any significant chronic disease or renal, hepatic or endocrine disease
    • * Current smokers
    • * Inability of patient to provide consent either for medical reasons or psychiatric reasons
Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 10 June 2022
  • First Submitted that Met QC Criteria 10 June 2022
  • First Posted 15 June 2022

Study Record Updates

  • Last Update Submitted that Met QC Criteria 20 March 2024
  • Last Update Posted 22 March 2024
  • Last Verified March 2024